EUVIMEDEUVIMED entdecken
Open Access · CC BY 4.0

Propensity matched comparison of omaveloxolone treatment to Friedreich ataxia natural history data

David R Lynch iD, Angie Goldsberry, Christian Rummey iD, Jennifer Farmer, Sylvia Boesch, Martin B Delatycki, Paola Giunti, J Chad Hoyle, Caterina Mariotti iD, Katherine D Mathews, Wolfgang Nachbauer, Susan Perlman und 5 weitere

Annals of Clinical and Translational Neurology · 2024-01 · 11 (1) · 4-16

DOI: 10.1002/acn3.51897 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Annals of Clinical and Translational Neurology, online erschienen am 10.09.2023. Verfasst von David R Lynch und 16 weiteren Autor:innen. Beteiligte Einrichtung: Departments of Pediatrics and Neurology, The Children's Hospital of Philadelphia, Philadelphia, Pennsylvania, USA. Hauptthemen laut MEDLINE: Friedreich Ataxia, Triterpenes. Die Arbeit wurde bisher 64-mal zitiert (Crossref) und nennt 31 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: Reata Pharmaceutical.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Objective

The natural history of Friedreich ataxia is being investigated in a multi‐center longitudinal study designated the Friedreich ataxia Clinical Outcome Measures Study (FACOMS). To understand the utility of this study in analysis of clinical trials, we performed a propensity‐matched comparison of data from the open‐label MOXIe extension (omaveloxolone) to that from FACOMS.

Methods

MOXIe extension patients were matched to FACOMS patients using logistic regression to estimate propensity scores based on multiple covariates: sex, baseline age, age of onset, baseline modified Friedreich Ataxia Rating scale (mFARS) score, and baseline gait score. The change from baseline in mFARS at Year 3 for the MOXIe extension patients compared to the matched FACOMS patients was analyzed as the primary efficacy endpoint using mixed model repeated measures analysis.

Results

Data from the MOXIe extension show that omaveloxolone provided persistent benefit over 3 years when compared to an untreated, matched cohort from FACOMS. At each year, in all analysis populations, patients in the MOXIe extension experienced a smaller change from baseline in mFARS score than matched FACOMS patients. In the primary pooled population (136 patients in each group) by Year 3, patients in the FACOMS matched set progressed 6.6 points whereas patients treated with omaveloxolone in MOXIe extension progressed 3 points (difference = −3.6; nominal p value = 0.0001).

Interpretation

These results suggest a meaningful slowing of Friedreich ataxia progression with omaveloxolone, and consequently detail how propensity‐matched analysis may contribute to understanding of effects of therapeutic agents. This demonstrates the direct value of natural history studies in clinical trial evaluations.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Friedreich AtaxiaTriterpenesHumansLongitudinal StudiesOutcome Assessment, Health CareMaleFemaleClinical Trials as Topic

Substanzen

omaveloxoloneTriterpenes

Autor:innen und Institutionen

  • Departments of Pediatrics and Neurology, The Children's Hospital of Philadelphia, Philadelphia, Pennsylvania, USA.
  • Perelman School of Medicine, University of Pennsylvania, Philadelphia, Pennsylvania, USA.
  • Reata Pharmaceuticals, Dallas, Texas, USA.
  • Clinical Data Science GmbH, Basel, Switzerland.
  • Friedreich Ataxia Research Alliance, Downingtown, Pennsylvania, USA.
  • Department of Neurology, Medical University Innsbruck, Innsbruck, Austria.

ORCID-Profile: David R Lynch, Christian Rummey, Caterina Mariotti, S H Subramony

Förderung

  • Reata Pharmaceutical

Zitieren

APA

Lynch, D. R., Goldsberry, A., Rummey, C., Farmer, J., Boesch, S., Delatycki, M. B., Giunti, P., Hoyle, J. C., Mariotti, C., Mathews, K. D., Nachbauer, W., Perlman, S., Subramony, S. H., Wilmot, G., Zesiewicz, T., Weissfeld, L., & Meyer, C. (2024). Propensity matched comparison of omaveloxolone treatment to Friedreich ataxia natural history data. Annals of Clinical and Translational Neurology, 11(1), 4-16. https://doi.org/10.1002/acn3.51897

Vancouver

Lynch DR, Goldsberry A, Rummey C, Farmer J, Boesch S, Delatycki MB, et al. Propensity matched comparison of omaveloxolone treatment to Friedreich ataxia natural history data. Annals of Clinical and Translational Neurology. 2024;11(1):4-16. doi:10.1002/acn3.51897

BibTeX
@article{Lynch2024,
  author = {Lynch, David R and Goldsberry, Angie and Rummey, Christian and Farmer, Jennifer and Boesch, Sylvia and Delatycki, Martin B and Giunti, Paola and Hoyle, J Chad and Mariotti, Caterina and Mathews, Katherine D and Nachbauer, Wolfgang and Perlman, Susan and Subramony, S H and Wilmot, George and Zesiewicz, Theresa and Weissfeld, Lisa and Meyer, Colin},
  title = {Propensity matched comparison of omaveloxolone treatment to Friedreich ataxia natural history data},
  journal = {Annals of Clinical and Translational Neurology},
  year = {2024},
  volume = {11},
  number = {1},
  pages = {4--16},
  doi = {10.1002/acn3.51897}
}
Kostenlos starten →